BHCHX Holdings — Baron Health Care Fund
All 43 reported holdings of Baron Health Care Fund (BHCHX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Eli Lilly & Co | 13.66% | $15.59M |
| Mettler-Toledo International Inc | 5.60% | $6.39M |
| Johnson & Johnson | 5.56% | $6.35M |
| Argenx SE | 4.23% | $4.82M |
| Thermo Fisher Scientific Inc | 3.91% | $4.46M |
| Roivant Sciences Ltd | 3.88% | $4.42M |
| Teva Pharmaceutical Industries Ltd | 3.86% | $4.40M |
| Welltower Inc | 3.38% | $3.86M |
| UnitedHealth Group Inc | 3.28% | $3.74M |
| RadNet Inc | 3.24% | $3.70M |
| Billiontoone Inc | 2.84% | $3.24M |
| Edwards Lifesciences Corp | 2.64% | $3.01M |
| Vertex Pharmaceuticals Inc | 2.61% | $2.98M |
| AstraZeneca PLC | 2.49% | $2.84M |
| Merck & Co Inc | 2.48% | $2.83M |
| Guardant Health Inc | 2.17% | $2.48M |
| Madrigal Pharmaceuticals Inc | 2.12% | $2.42M |
| Revolution Medicines Inc | 2.05% | $2.34M |
| Elanco Animal Health Inc | 2.05% | $2.34M |
| Kymera Therapeutics Inc | 2.01% | $2.29M |
| Gilead Sciences Inc | 1.99% | $2.27M |
| Natera Inc | 1.93% | $2.20M |
| Intuitive Surgical Inc | 1.74% | $1.99M |
| Protagonist Therapeutics Inc | 1.72% | $1.96M |
| Elevance Health Inc | 1.69% | $1.93M |
| Repligen Corp | 1.49% | $1.71M |
| Xenon Pharmaceuticals Inc | 1.32% | $1.51M |
| HeartFlow Inc | 1.26% | $1.43M |
| Ionis Pharmaceuticals Inc | 1.25% | $1.43M |
| IDEXX Laboratories Inc | 1.20% | $1.37M |
| Dexcom Inc | 1.18% | $1.35M |
| VeraDermics Inc | 1.08% | $1.23M |
| Insmed Inc | 0.93% | $1.07M |
| Arcutis Biotherapeutics Inc | 0.80% | $917.70K |
| Sartorius Stedim Biotech | 0.73% | $829.41K |
| Axsome Therapeutics Inc | 0.64% | $734.31K |
| Cytokinetics Inc | 0.63% | $724.12K |
| Definium Therapeutics Inc | 0.57% | $651.74K |
| Ascendis Pharma A/S | 0.35% | $400.08K |
| Tango Therapeutics Inc | 0.34% | $390.75K |
| Abivax SA | 0.29% | $333.15K |
| Newamsterdam Pharma Co NV | 0.27% | $305.01K |
| Enliven Therapeutics Inc | 0.22% | $253.75K |
BHCHX overview: performance, fees, allocation and SEC filings